ARS Pharmaceuticals reported $32.5 million in revenue for Q3 2025, primarily from neffy epinephrine nasal spray sales. The company continues to expand market presence through direct-to-consumer campaigns and has strong cash reserves of $288.2 million.

Pediatrix Medical Group reported strong Q2 2025 earnings, with non-GAAP EPS of $0.53 beating analyst expectations. Despite a 7.4% revenue decline due to practice divestitures, the company showed growth in hospital-based neonatal services and raised its adjusted EBITDA guidance.

MONTRÉAL, 25 juin 2024 (GLOBE NEWSWIRE) -- Exploration Midland inc. (« Midland ») (TSX-V: MD), en partenariat avec Probe Gold Inc. (« Probe »), a le plaisir d’annoncer la reprise des travaux d’exploration sur la découverte d’un système minéralisé en cuivre-or-argent-molybdène (« Cu-Au-Ag-Mo ») effectuée en 2022 sur la propriété La Peltrie Option (« la Propriété »). Cet important système minéralisé est situé à 15 kilomètres au sud-est du gîte aurifère Zone 58N détenu par Agnico Eagle et à 25 kilomètres à l’ouest de l’ancienne mine Selbaie qui a produit 56,9 Mt titrant 0,87% Cu, 1,85% Zn, 39 g/t Ag et 0,55 g/t Au (production historique).

MONTREAL, June 25, 2024 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with Probe Gold Inc. (“Probe”), is pleased to announce that exploration work will resume on the copper-gold-silver-molybdenum (“Cu-Au-Ag-Mo”) discovery made in 2022 on the La Peltrie Option (the “Property”). This significant mineralized system is located 15 kilometres southeast of Agnico Eagle’s Zone 58N gold deposit and 25 kilometres west of the former Selbaie mine, which produced 56.9 Mt grading 0.87% Cu, 1.85% Zn, 39 g/t Ag, and 0.55 g/t Au (historical production).

Investors need to pay close attention to Pediatrix Medical (MD) stock based on the movements in the options market lately.

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MONTRÉAL, 04 juin 2024 (GLOBE NEWSWIRE) -- Exploration Midland inc. (« Midland ») (TSX-V : MD) a le plaisir d’annoncer son programme d’exploration pour l’été 2024 dans le cadre de l’alliance stratégique (« l’Alliance ») avec SOQUEM inc. (« SOQUEM ») pour l’exploration de la Fosse du Labrador au Nunavik. Ce programme, d’un budget conjoint d’1 million $, s’inscrit dans la continuité des travaux effectués depuis 2021. Ces travaux visent à identifier de nouveaux secteurs minéralisés dans ce vaste territoire à haut potentiel de découverte.

MONTREAL, June 04, 2024 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce its summer 2024 exploration program under the Strategic Alliance (the “Alliance”) with SOQUEM Inc. (“SOQUEM”) for exploration in the Labrador Trough in Nunavik. With a joint budget of $1 million, this program is the continuation of work carried out since 2021 and aims to identify new mineralized areas in this vast territory with high-discovery potential.

In the preceding three months, 4 analysts have released ratings for Pediatrix Medical Group (NYSE:MD), presenting a wide array of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 3 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $9.5, a high estimate of $10.00, and a low estimate of $9.00. This current average has decreased by 6.13% from the previous average price target of $10.12. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Pediatrix Medical Group by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Macdonald Truist Securities Maintains Hold $10.00 $10.00 Brian Tanquilut Jefferies Lowers Hold $9.00 $10.00 Ann Hynes Mizuho Lowers Neutral $9.00 $10.00 David Macdonald Truist Securities Lowers Hold $10.00 $10.50 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Pediatrix Medical Group. This ...Full story available on Benzinga.com

Pediatrix's (MD) Q1 results benefit from higher same-unit revenues, resulting from growing patient volumes, partly offset by high costs. It continues to expect 2024 adjusted EBITDA within $200-$220 million.

The headline numbers for Pediatrix Medical Group (MD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Life Time Group Holdings (LTH) delivered earnings and revenue surprises of -6.25% and 1.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?